Thyroid Disease and Heart Disease in Men: The Overlooked Connection

Thyroid disease is often framed as a women’s condition: Hashimoto’s thyroiditis and Graves’ disease both have strong female predominance. But thyroid dysfunction in men carries significant cardiovascular consequences that are frequently underrecognized because men are less often screened and less often suspected. Hypothyroidism elevates LDL-C, raises blood pressure, promotes cardiac dysfunction, and worsens insulin resistance. Hyperthyroidism drives atrial fibrillation, precipitates heart failure, and causes a catabolic state that masks underlying cardiac vulnerability. When thyroid disease is identified in a man with cardiovascular disease, it is not an incidental finding; it is a cardiovascular modifier.

The clinical cost of missing thyroid disease in a man presenting to cardiology is high. A man with new-onset atrial fibrillation from undiagnosed hyperthyroidism who receives rate control and anticoagulation without thyroid evaluation will be incompletely treated, the arrhythmia will not resolve until the thyroid state normalizes. A man with LDL-C of 200 mg/dL from hypothyroidism who is escalated to high-intensity statin or PCSK9 inhibitor without treating the underlying thyroid deficit is receiving more aggressive lipid management than necessary. The reversible secondary contributor is not rare; it is simply underlooked in men.

Why Men Are Undertested

The female predominance of autoimmune thyroid disease is real and substantial. Hashimoto’s thyroiditis occurs approximately 7 to 10 times more frequently in women than men. Graves’ disease has a similar female-to-male ratio. This epidemiological reality has created a clinical heuristic that thyroid disease is a women’s health issue, which translates into lower rates of thyroid function testing in male patients across primary care and cardiology settings.

But the female predominance of autoimmune thyroid disease does not mean thyroid dysfunction is rare in men; it means the absolute case count is lower. Overt hypothyroidism from any cause occurs in approximately 2 to 3% of adult men, with rates increasing substantially with age. Non-autoimmune causes of thyroid dysfunction, including thyroid nodules with functional autonomy, post-radioiodine treatment for prior hyperthyroidism, prior thyroid surgery, iodine deficiency in regions where it persists, and medication-induced thyroid dysfunction, affect men at meaningful rates that do not reflect the sex skew of autoimmune thyroid disease.

Men also underreport thyroid symptoms. The hallmark symptoms of hypothyroidism, fatigue, weight gain, cold intolerance, constipation, cognitive slowing, reduced libido, depression, and dry skin, are frequently attributed to other causes in men: aging, sedentary lifestyle, work-related stress, alcohol use, or simply being “tired.” In clinical practice, the threshold for a male patient volunteering thyroid-type symptoms is higher, and the threshold for a clinician proactively ordering thyroid tests in a male patient is also higher. This creates a systematic underdetection bias.

The consequences of missing thyroid disease in men presenting to cardiology are particularly significant because thyroid dysfunction can masquerade as several primary cardiovascular conditions. The evidence shows that a focused thyroid evaluation should be part of the secondary workup for men presenting with unexplained new atrial fibrillation, refractory hypertension that does not respond adequately to standard antihypertensive regimens, dyslipidemia that is disproportionate to dietary and genetic history, and new-onset heart failure without clear cause.

Hypothyroidism and the Cardiovascular Profile

Overt hypothyroidism, defined as an elevated TSH with a low free T4, produces a distinctive cardiovascular risk profile that operates through multiple simultaneous mechanisms. Understanding each mechanism helps clarify both the cardiovascular risk and the expected trajectory of improvement with treatment.

LDL-C elevation is one of the most clinically actionable hypothyroid cardiovascular effects. Thyroid hormone normally upregulates hepatic LDL receptor expression, which increases clearance of LDL particles from the circulation. When thyroid hormone levels fall, LDL receptor expression decreases, LDL particle clearance slows, and serum LDL-C rises. This is a secondary dyslipidemia that is biochemically similar to familial hypercholesterolemia in its mechanism but reversible with thyroid hormone replacement. A man presenting with LDL-C of 180 to 220 mg/dL who has not been tested for thyroid function represents a missed diagnostic opportunity. LDL-C elevations from hypothyroidism will substantially resolve when euthyroid status is restored, which may render high-intensity statin therapy unnecessary or allow down-titration.

Hypertension from hypothyroidism is predominantly diastolic, driven by increased peripheral vascular resistance. Thyroid hormone normally causes vasodilation by stimulating nitric oxide production in vascular endothelium; hypothyroidism reduces this vasodilatory drive and increases systemic vascular resistance. Some cardiologists consider hypothyroidism one of the most common and most reversible causes of secondary hypertension. A man with diastolic hypertension that has been difficult to control despite multiple antihypertensive agents, and who has never had a TSH measured, should have thyroid function assessed.

Diastolic dysfunction is another cardiac effect of hypothyroidism. Thyroid hormone regulates the expression of key calcium handling proteins in the myocardium, particularly SERCA2a (sarco-endoplasmic reticulum calcium ATPase), which governs calcium re-uptake during myocardial relaxation. Hypothyroidism impairs SERCA2a expression, slowing calcium re-uptake and prolonging the relaxation phase of the cardiac cycle. The clinical result is impaired diastolic filling, reduced exercise tolerance, and in severe cases, clinical heart failure with preserved ejection fraction. This diastolic dysfunction is reversible with thyroid hormone replacement, often substantially within weeks to months of achieving euthyroid status.

Bradycardia is common in hypothyroid men and frequently goes unremarked because a resting heart rate of 50 to 60 bpm in a middle-aged male patient may be attributed to athletic conditioning rather than thyroid deficiency. Thyroid hormone normally increases chronotropic drive by sensitizing cardiac pacemaker cells to sympathetic stimulation; hypothyroidism reduces this effect, slowing intrinsic heart rate. In a man with resting bradycardia and fatigue who is neither an athlete nor on beta-blockers, hypothyroidism is a reasonable diagnostic consideration.

Pericardial effusion occurs in a subset of men with severe or longstanding hypothyroidism. The effusion in this context is typically slowly accumulating, high in cholesterol and protein, and may become quite large before causing hemodynamic compromise because the pericardium has time to gradually stretch. A man presenting with echocardiographic finding of a large pericardial effusion without prior cardiac surgery, active inflammation, or cancer history warrants thyroid evaluation.

Insulin resistance is worsened by hypothyroidism through effects on glucose metabolism, muscle glycogen turnover, and hepatic glucose production. For men who already have prediabetes or type 2 diabetes, hypothyroidism superimposes additional metabolic burden, worsening glycemic control. Some cardiologists note that when a diabetic man’s glycemic control suddenly deteriorates without clear dietary change or weight gain, thyroid function is worth checking.

Subclinical Hypothyroidism in Men

Subclinical hypothyroidism, defined as an elevated TSH with a normal free T4, is considerably more common than overt hypothyroidism and its cardiovascular relevance has been studied in large pooled datasets.

Evidence from a pooled individual participant data meta-analysis of 55,287 adults (Rodondi et al., JAMA, 2010) showed that subclinical hypothyroidism with a TSH of 10 mU/L or higher was associated with significantly elevated risk of heart failure and coronary artery disease compared to euthyroid individuals. The associations were stronger and more consistent at TSH values above 10 mU/L than at the 4.5 to 9.9 mU/L range, where the cardiovascular risk associations were present but more modest. 4 / Promising

The question of whether treating subclinical hypothyroidism improves cardiovascular outcomes is separate from the question of whether the association exists. The TRUST trial (Thyroid hormone Replacement for Untreated older adults with Subclinical hypothyroidism Trial), published in 2017, enrolled 737 older adults with TSH between 4.6 and 19.9 mU/L and found that levothyroxine replacement did not improve hypothyroid symptoms, fatigue, or quality of life measures compared to placebo in this elderly population. This finding has substantially moderated enthusiasm for treating subclinical hypothyroidism in older adults.

However, treatment decisions for subclinical hypothyroidism in men should be individualized based on several factors. In men under approximately 65 with TSH persistently above 10 mU/L on two measurements at least three months apart, treatment with levothyroxine has broader guideline support and is reasonable to consider. In men with subclinical hypothyroidism who have LDL-C elevation that has not responded adequately to statin therapy, treating the thyroid before escalating lipid management is a reasonable diagnostic and therapeutic step. If LDL-C normalizes after TSH normalization, the lipid problem was secondary; if LDL-C remains elevated after achieving euthyroid status, the dyslipidemia is primary and warrants its own treatment.

Antithyroid peroxidase (anti-TPO) antibodies predict progression from subclinical to overt hypothyroidism. A man with subclinical hypothyroidism and strongly positive anti-TPO antibodies has a higher likelihood of developing overt hypothyroidism over time, which supports closer monitoring and a lower threshold for treatment consideration.

Hyperthyroidism: The Arrhythmia Driver

Thyroid hormone exerts direct chronotropic and inotropic effects on the heart. It binds nuclear receptors that regulate the transcription of genes encoding key cardiac proteins, including myosin heavy chains, SERCA2a, phospholamban, and beta-adrenergic receptors. The net effect of excess thyroid hormone is a heart that beats faster, contracts more forcefully, and is more sensitive to sympathetic stimulation than normal. In a young, otherwise healthy man, this may produce uncomfortable palpitations and exertional intolerance. In an older man with underlying cardiac disease, it can precipitate atrial fibrillation, heart failure, and angina.

Atrial fibrillation is one of the most important cardiovascular complications of hyperthyroidism in men. Thyrotoxicosis is found in approximately 10 to 15% of presentations of new atrial fibrillation, a rate that justifies thyroid testing in all men presenting with unexplained new AF. The mechanism is a combination of elevated sympathetic tone, direct atrial electrophysiological effects of thyroid hormone (shortening atrial refractory periods), and the hemodynamic consequences of high-output state on atrial size and pressure.

Thyrotoxic atrial fibrillation is frequently rate-uncontrolled with standard beta-blocker doses because the excess thyroid hormone sensitizes the heart to catecholamines in ways that may override standard beta-blockade. Rate control in thyrotoxic AF typically requires higher beta-blocker doses and may also require the addition of a calcium channel blocker. Definitive rhythm and rate management, however, requires treating the underlying thyroid disease. Cardioversion of thyrotoxic AF before euthyroid status is restored has a high recurrence rate because the atrial milieu that caused the AF remains unchanged.

High-output heart failure from hyperthyroidism can closely mimic dilated cardiomyopathy or high-output cardiac states from other causes. The distinguishing features include wide pulse pressure, bounding peripheral pulses, evidence of increased cardiac output on echocardiogram, and the accompanying thyrotoxic symptoms. When thyroid disease is the cause, the cardiac function frequently recovers substantially after treatment restores euthyroid status, particularly when treatment is prompt.

Overt hyperthyroidism also produces a catabolic state that includes muscle wasting, including of the myocardium. In men with underlying coronary artery disease, the combination of increased myocardial oxygen demand (from tachycardia and increased contractility) and reduced oxygen supply (from existing atherosclerosis) can precipitate unstable angina or acute coronary syndrome. This intersection of thyroid disease and coronary disease in men can be clinically severe.

Amiodarone and Thyroid in Men

Amiodarone is a commonly used antiarrhythmic agent for both atrial fibrillation and ventricular arrhythmias. Its relationship with thyroid function is complex, clinically important, and warrants detailed discussion because amiodarone is used predominantly in older men with structural heart disease.

Amiodarone contains approximately 37% iodine by weight, and because it is stored extensively in adipose tissue, it continues to release iodine into the circulation for months to years after the drug is stopped. Its iodine content and pharmacological effects on thyroid hormone metabolism make it one of the most thyrotoxic medications in common cardiovascular use.

Amiodarone-induced hypothyroidism (AIH) occurs in approximately 14 to 22% of patients taking amiodarone in iodine-sufficient regions. The mechanism involves the Wolff-Chaikoff effect, excess iodine suppresses thyroid hormone synthesis, that fails to escape in susceptible individuals, leading to hypothyroidism. Men with preexisting autoimmune thyroid disease (detectable anti-TPO antibodies) are at higher risk for AIH. Treatment is levothyroxine supplementation. Amiodarone does not need to be stopped to treat AIH, and continuation is often preferable given the cardiac indication.

Amiodarone-induced thyrotoxicosis (AIT) occurs in approximately 5 to 10% of amiodarone-treated patients in iodine-sufficient regions. There are two distinct types with different mechanisms and treatments. Type 1 AIT occurs in men with pre-existing thyroid disease (autonomous nodules, subclinical Graves’ disease) where excess iodine from amiodarone acts as a substrate for unregulated thyroid hormone synthesis. Type 2 AIT is a destructive thyroiditis in which amiodarone directly damages thyroid follicles, releasing stored preformed thyroid hormone. Type 1 requires antithyroid medications (thionamides); Type 2 is treated with glucocorticoids. Mixed AIT occurs in both types simultaneously and is more challenging to manage.

AIT in the context of structural heart disease is a cardiovascular emergency. A man with ischemic cardiomyopathy or AF managed with amiodarone who develops thyrotoxicosis is now contending with a high-output, tachycardic state superimposed on a heart with limited reserve. The hemodynamic consequences can be rapidly destabilizing. Early recognition requires that TSH monitoring be part of the routine follow-up for all men on amiodarone.

All men started on amiodarone should have baseline assessment including TSH, free T4, and antithyroid antibodies before initiating therapy, followed by TSH and free T4 monitoring every six months while on the drug.

Monitoring After Thyroid Treatment

The cardiovascular implications of thyroid treatment in men are as important as the diagnosis itself, and monitoring should be explicitly planned at the time treatment begins.

Men started on levothyroxine for hypothyroidism should have LDL-C rechecked 8 to 12 weeks after TSH normalization. The secondary dyslipidemia from hypothyroidism should substantially resolve during this period. If LDL-C normalizes after achieving euthyroid status, the hypercholesterolemia was entirely secondary to thyroid disease and statin therapy may not be required. If LDL-C remains elevated above treatment thresholds after confirmed euthyroid status, the residual dyslipidemia reflects primary hypercholesterolemia and warrants its own management including statin consideration.

TSH monitoring after levothyroxine initiation follows a standard schedule: recheck at 6 to 8 weeks after initiation or any dose change, then every 6 to 12 months once a stable TSH is established. The target TSH for most men on thyroid hormone replacement is within the lower half of the normal reference range, generally 0.5 to 2.5 mU/L, though institutional reference ranges vary. Overtreatment with levothyroxine, which produces a suppressed TSH, carries its own cardiovascular risks including atrial fibrillation and bone loss.

Men on levothyroxine who develop new palpitations, worsening hypertension, or unexplained AF should have urgent TSH measurement to evaluate for iatrogenic hyperthyroidism from overtreatment. Dose adjustments in older men should be made in small increments because the heart’s sensitivity to thyroid hormone increases with age, and cardiac adverse effects from relatively modest TSH suppression are more pronounced in men over 65.

Post-radioiodine treatment for Graves’ disease produces hypothyroidism in essentially all treated men, either immediately or within six to twelve months. These men require lifetime levothyroxine replacement and ongoing cardiovascular monitoring that accounts for their prior Graves’ disease history. The cardiac remodeling from years of hyperthyroidism, including atrial enlargement and potentially persistent atrial fibrillation, may not fully resolve even after euthyroid status is achieved.

Men who undergo total thyroidectomy for thyroid cancer and receive TSH-suppressive levothyroxine dosing (targeting TSH near zero to reduce thyroid cancer stimulation) face an intentionally thyrotoxic state that carries cardiovascular implications. Some oncology protocols have liberalized TSH targets in low-risk thyroid cancer survivors, allowing TSH to be maintained in the lower-normal range rather than suppressed. Cardiologists managing men in this situation should be aware of the competing oncologic and cardiovascular considerations.

Synthesis

The thyroid-cardiovascular connection in men is not exotic cardiology; it is practical, high-yield secondary evaluation that is systematically underperformed because of a persistent clinical heuristic that thyroid disease belongs to women’s medicine. This heuristic is understandable given the female predominance of autoimmune thyroid disease, but it has real clinical costs when it leads to missed secondary causes of cardiovascular disease in male patients.

The cardiovascular effects of hypothyroidism in men, secondary LDL elevation, diastolic hypertension, bradycardia, diastolic dysfunction, and worsened insulin resistance, are collectively responsible for meaningful cardiovascular risk. These effects are reversible. A man whose LDL drops from 210 to 130 mg/dL after treating his hypothyroidism has experienced a 30% absolute risk reduction in LDL without statin escalation. The diagnostic yield of checking a TSH in a man with unexplained dyslipidemia or refractory hypertension is too high to omit as a matter of routine evaluation.

Hyperthyroidism in men is a cardiovascular urgency when it produces atrial fibrillation or heart failure, and the cardiovascular sequelae will not fully resolve until the thyroid state is normalized. Rate control without treating the thyroid is partial treatment. For men on amiodarone, the drug’s profound thyroid effects make routine monitoring not optional but necessary.

The evidence shows that integrating thyroid evaluation into the cardiovascular workup of men with unexplained or resistant presentations represents a practical, inexpensive, and potentially high-yield step. Some cardiologists routinely include TSH in the initial evaluation of new male AF and refractory hypertension. That approach reflects a well-grounded awareness of how frequently thyroid disease and cardiovascular disease intersect, and how often the intersection goes unremarked until the thyroid result comes back abnormal.

The Signal Check is fifteen questions mapping the male cardiovascular risk pattern, including the physiological domains most commonly missed in standard screenings. It produces a specific starting point for your next clinical conversation.